

PHARMACEUTICAL 2023

Kura Oncology Inc. Rank 58 of 446







RealRate

PHARMACEUTICAL 2023

Kura Oncology Inc. Rank 58 of 446

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Kura Oncology Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 194% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	446,426
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,057
Liabilities, Non-Current	11,971
Other Assets	7,340
Other Compr. Net Income	-6,243
Other Expenses	0
Other Liabilities	0
Other Net Income	4,025
Other Revenues	0
Property and Equipment	2,540
Research and Development	92,812
Selling, General and Administrative Expense	47,053

Output Variable	Value in 1000 USD
Assets	456,306
Liabilities	36,028
Expenses	139,865
Revenues	0
Stockholders Equity	420,278
Net Income	-135,840
Comprehensive Net Income	-138,962
Economic Capital Ratio	237%

